Scotts Miracle-Gro (SMG) stays a buy: turnaround, lower leverage, secure 4% dividend, resilient demand and manageable costs.
Duopharma Biotech Bhd is expected to remain resilient despite geopolitical uncertainties, supported by limited exposure to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results